Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2025.07.014 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Marta Brambilla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino Istituto di Ricovero e Cura a Carattere Scientifico, Milan…. Hauptthemen laut MEDLINE: Blood Platelets, Coronary Artery Disease, Platelet Activation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Walter and Eliza Hall Institute of Medical Research, University of Melbourne.
Abstract (Originalsprache)
BACKGROUND: Given the role of platelets in coronary artery disease (CAD), assessment of a soluble platelet-activation marker may be useful to improve thrombotic risk stratification. OBJECTIVES: This study aimed to perform a meta-analysis investigating the association between levels of 14 such markers associated with CAD. METHODS: PubMed, Web of Science, and Excerpta Medica dataBASE (EMBASE) were searched until November 2024. The primary end point was the difference in levels of 11-dehydro-thromboxane B2, 2,3-dinor-thromboxane B2, β-thromboglobulin, soluble CD40L (sCD40L), glycocalicin, glycoprotein (GP)V, GPVI, matrix metalloproteinase (MMP)-9 and MMP-2, platelet factor (PF)4, soluble (s) P-selectin, SCUBE1, serotonin and thrombospondin (TSP)-1 between patients with CAD and healthy subjects (HSs) in plasma and/or serum. When possible, patients with CAD were stratified into acute coronary syndrome (ACS) and chronic coronary disease. Standardized mean difference (SMD) was calculated. RESULTS: Due to heterogeneity in the assessed studies, meta-analysis was performed for sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, SCUBE1, and TSP-1. All markers but TSP-1 were significantly elevated in patients with CAD compared with HSs. Differences in sCD40L and SCUBE1 were statistically significant only when studies that assessed plasma were combined with those that assessed serum. When compared with HSs, the differences were bigger in patients with ACS than patients with chronic coronary disease for MMP-9 (SMD, 2.49 vs 0.49), PF4 (SMD, 2.01 vs 0.96), and sP-selectin (SMD, 1.81 vs 0.63). Publication bias was identified for sCD40L and, in ACS, for sP-selectin and PF4. CONCLUSION: The increased levels of sCD40L, soluble GPV, MMP-9, PF4, sP-selectin, and SCUBE1 in patients with CAD compared with HSs provide a rationale for designing new studies to address the potential of such molecules as biomarkers for thrombotic risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.
- Department of Clinical Chemistry, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Laboratory Medicine, Institute of Biomedicine, The University of Gothenburg, Gothenburg, Swede…
- Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Pharmacy, Università degli Studi di Napoli Federico II, Naples, Italy.
- Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, Naples, Italy. Electronic address: https://twitter.com/MNDDM81.
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Förderung
- Walter and Eliza Hall Institute of Medical Research
- University of Melbourne
Zitieren
APA
Brambilla, M., Josefsson, E. C., Ramstrom, S., Di Minno, A., Di Minno, M. N. D., Gangatirkar, P., Moujalled, D., Becchetti, A., Lordkipanidzé, M., & Camera, M. (2025). Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.07.014
Vancouver
Brambilla M, Josefsson EC, Ramstrom S, Di Minno A, Di Minno MND, Gangatirkar P, et al. Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.07.014
BibTeX
@article{Brambilla2025,
author = {Brambilla, Marta and Josefsson, Emma C and Ramstrom, Sofia and Di Minno, Alessandro and Di Minno, Matteo Nicola Dario and Gangatirkar, Pradnya and Moujalled, Diane and Becchetti, Alessia and Lordkipanidzé, Marie and Camera, Marina},
title = {Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2025.07.014}
}
EUVIMED